Standard TB Tests Miss Critical Drug-Resistance Mutations, Study Warns

Tuberculosis has long been a disease of incomplete information. A patient arrives at a clinic with a persistent cough. A sample is taken. A test comes back. The doctor prescribes the standard drugs. But what if the bacteria inside that patient has already learned to resist them? What if the test itself—the one approved by the World Health Organization, the one used in clinics across the world—is blind to the very mutations that would reveal this resistance?

Researchers at IIT Guwahati and IIT Madras have documented a troubling gap in how the world detects drug-resistant tuberculosis. The standard tests that clinicians rely on examine only a narrow slice of the rpoB gene, a region called the rifampicin resistance-determining region, or RRDR. This section contains 81 base pairs of DNA. It is where many resistance mutations cluster. But it is not where all of them live. Mutations that confer resistance to rifampicin—one of the most powerful drugs in the TB arsenal—can and do occur elsewhere in the gene. When they do, the standard tests miss them entirely.

The consequence is straightforward and grim. A patient whose TB bacteria carry these undetected mutations receives treatment that will not work. The bacteria continue to replicate. The infection persists. And because the resistance has gone unrecognized, the patient remains in the community, coughing, spreading drug-resistant strains to family members, coworkers, and others. What should have been a contained medical problem becomes a public health crisis.

The researchers identified two mechanisms by which these hidden mutations cause resistance. In the first, the mutation alters the shape of the protein that rifampicin targets, preventing the drug from latching on and doing its job. In the second, mutations outside the RRDR can work in concert with conventional resistance mutations, essentially helping the bacteria regain the strength and vigor it lost when it first became resistant. These compensatory mutations allow drug-resistant strains to survive and spread more efficiently than they otherwise would.

The real-world evidence is not theoretical. In Eswatini, researchers examining drug-resistant TB cases found that 30 percent of them carried these additional mutations—mutations that standard tests failed to detect. Similar findings emerged from Northeast India, Peru, and South Africa. In each case, the pattern was the same: patients with unidentified resistance continued to receive ineffective treatment while their resistant bacteria circulated unchecked.

The implications ripple outward. TB control programs worldwide depend on accurate detection to guide treatment decisions and contain spread. When the detection system has blind spots, the entire strategy falters. A patient who should be flagged for second-line drugs instead receives first-line therapy. A resistant strain that should trigger isolation protocols instead moves freely through a community. The disease evolves faster than our ability to track it.

The researchers are not calling for the abandonment of current tests. Rather, they are sounding an alarm about the limitations of relying on a single genetic region, no matter how carefully chosen. The RRDR was identified because it is a hotspot for resistance mutations. But hotspots are not the whole story. The world's TB programs need enhanced testing methods—approaches that can capture the full spectrum of resistance-causing mutations, not just the ones that happen to cluster in one well-studied stretch of DNA. Until that happens, an unknown number of patients will receive treatment that cannot save them, and an unknown number of resistant strains will spread unchecked.